Galectin-9是检测SLE和APS干扰素特征易测生物标志物
该研究在SLE、SLE+APS、原发性APS患者及健康对照(n=148)中检测血清galectin-9、CXCL-10和TNF-RII水平,并与疾病活动度和干扰素特征相关分析。结果显示galectin-9与干扰素评分相关性最强(r=0.70,p<0.001),检测干扰素特征的AUC为0.86,优于CXCL-10、TNF-RII、抗dsDNA抗体及补体C3/C4。结论认为galectin-9是易于测量、临床可用的干扰素特征生物标志物。
要点
- Galectin-9与干扰素评分相关性最强(r=0.70,p<0.001)。
- Galectin-9检测干扰素特征的AUC为0.86,优于CXCL-10和TNF-RII。
- 在SLE(±APS)患者中,galectin-9检测干扰素特征优于抗dsDNA抗体(AUC 0.70)及补体C3(AUC 0.70)、C4(AUC 0.78)。
核心结论
- Galectin-9是一种新型、易于测量因而临床可用的生物标志物,可用于检测SLE和APS等系统性自身免疫病患者的干扰素特征。
研究设计与样本
- 研究先在较小队列(n=43)中筛选血清分析物,随后在SLE、SLE+APS、原发性APS患者及健康对照(n=148)中测量galectin-9、CXCL-10和TNF-RII血清水平。
- 将分析物与疾病活动度指标及干扰素特征进行相关性分析,并用受试者工作特征曲线评估galectin-9、CXCL-10和TNF-RII检测干扰素特征的表现。
主要发现
- Galectin-9、CXCL-10和TNF-RII在SLE、SLE+APS和原发性APS患者中升高(p<0.05),并与疾病活动度和组织因子表达相关。
- Galectin-9与干扰素评分的相关性(r=0.70,p<0.001)强于CXCL-10或TNF-RII。
- Galectin-9检测干扰素特征的AUC为0.86,优于CXCL-10或TNF-RII。
- 在SLE(±APS)患者中,galectin-9检测干扰素特征亦优于抗dsDNA抗体(AUC 0.70)及补体C3(AUC 0.70)、C4(AUC 0.78)水平。
关键数值与推荐
- Galectin-9与干扰素评分的相关系数r=0.70,p<0.001。
- Galectin-9检测干扰素特征的AUC为0.86。
- 抗dsDNA抗体检测干扰素特征的AUC为0.70,补体C3为0.70,补体C4为0.78。
临床怎么用
- Galectin-9可作为易于测量的血清生物标志物,用于检测SLE和APS患者的干扰素特征,替代基因表达分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The interferon (IFN) signature is related to disease activity and vascular disease in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) and represents a promising therapeutic target. Quantification of the IFN signature is currently performed by gene expression analysis, limiting its current applicability in clinical practice. Therefore, the objective of this study was to establish an easy to measure biomarker for the IFN signature. METHODS: Serum levels of galectin-9, CXCL-10 (IP-10) and tumour necrosis factor receptor type II (TNF-RII) were measured in patients with SLE, SLE+APS and primary APS (PAPS) and healthy controls (n=148) after an initial screening of serum analytes in a smaller cohort (n=43). Analytes were correlated to measures of disease activity and the IFN signature. The performance of galectin-9, CXCL-10 and TNF-RII as biomarkers to detect the IFN signature was assessed by receiver operating characteristic curves. RESULTS: Galectin-9, CXCL-10 and TNF-RII were elevated in patients with SLE, SLE+APS and PAPS (p<0.05) and correlated with disease activity and tissue factor expression. Galectin-9 correlated stronger than CXCL-10 or TNF-RII with the IFN score (r=0.70, p<0.001) and was superior to CXCL-10 or TNF-RII in detecting the IFN signature (area under the curve (AUC) 0.86). Importantly, in patients with SLE(±APS), galectin-9 was also superior to anti-dsDNA antibody (AUC 0.70), or complement C3 (AUC 0.70) and C4 (AUC 0.78) levels in detecting the IFN signature. CONCLUSION: Galectin-9 is a novel, easy to measure hence clinically applicable biomarker to detect the IFN signature in patients with systemic autoimmune diseases such as SLE and APS.
引用
- van den Hoogen LL, van Roon JAG, Mertens JS, et al. Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2018. PMID: 30185417. doi:10.1136/annrheumdis-2018-213497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。